BioLineRx
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2 Hama'ayan St, Modi’in, Central Distric...Phone Number
+972 86429100Website
www.biolinerx.comRevenue
$12.7 MillionStock Symbol
BLRXIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BioLineRx
BioLineRx Ltd. is a pre-commercial biopharmaceutical company focused on developing innovative therapies for certain cancers and rare diseases. Its pipeline includes investigational treatments for multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel with U.S. operations, BioLineRx combines end-to-end development and commercialization capabilities to translate scientific discoveries into potentially life-changing medicines for patients.Explore more
BioLineRx Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioLineRx your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
BioLineRx, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BioLineRx has recently received funding, and reach out quickly before it becomes old news!
Click to see if BioLineRx had a recent Job posting/layoffs
Product Launch: Get notified when BioLineRx launches new products
Check out if BioLineRx is spiking on competitors!
Funding: Get notified immidiatlly once BioLineRx has new funding data
Earning: See what the market has to say on BioLineRx recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at BioLineRx
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
BioLineRx is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioLineRx is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioLineRx.
BioLineRx financials insights
Gather financial insights about BioLineRx, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2007
Stock Offering
$50M
2022
Debt
$40M
2023
Other Financing Round
$15M
2024
Debt
$20M
BioLineRx Tech Stack
A closer look at the technologies used by BioLineRx
Most Recent Scoops
Person-Based
Medical Research, Clinical Operations
Person-Based
Medical Research, Clinical Operations
Person-Based
Earnings, Business Finance, Finance, Financial Operations
Earnings
Earnings, Finance
Person-Based
Medical Research, Pharmaceuticals, Clinical Operations
BioLineRx News & Media
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
TEL AVIV, Israel and OSLO, Norway, July 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel...BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call Transcript
BioLineRx Ltd. (BLRX) Q1 2026 Earnings Call May 27, 2026 8:30 AM EDTCompany ParticipantsPhilip Serlin - Chief Executive OfficerMali Zeevi - Chief Financial...BioLineRx Shares Advance After First Patient Enrolled in GLIX1 Cancer Study (BLRX)
BioLineRx Ltd. (NASDAQ:BLRX) reported first-quarter 2026 financial results on Wednesday, shortly after announcing that the first patient had been dosed in its Phase 1/2a clinical study evaluating GLIX1 for the treatment of glioblastoma.BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) - - Announced new GLIX1 data demonstrating potent anti-tumor effect in GBM across multiple in-vivo studies, including a temozolomide (TMZ)-resistant patient-derived xenograft model -...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioLineRx
Sign Up For FreeTo access detailed company insights
BioLineRx Ltd. is a pre-commercial biopharmaceutical company focused on developing innovative therapies for certain cancers and rare diseases. Its pipeline includes investigational treatments for multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel with U.S. operations, BioLineRx combines end-to-... Read More
